Supplemental Comment from Kenvue Brands LLC part 3 of 9
AnonymousOtherBusiness
Summary: Kenvue Brands LLC submitted a supplemental response to a citizen petition regarding the safety of prenatal acetaminophen (APAP) exposure. The document provides a detailed review of literature and meta-analyses concerning the association between prenatal APAP use and various neurobehavioral and urogenital outcomes in children.
Kenvue Brands LLC’s supplemental response to the Citizen Petition part 3 of 9
Attachments
- Brown et al. (2017)
- Brynge et al. (2022)
- Brzezinski et al. (1999)
- Carder et al. (1990)
- CDER Epidemiology_Review of Published Studies (2022) (PDF)
- Chakrabarti and Fombonne (2005)
- Chopyk et al. (2019)
- Clancy et al. (2007)
- Coles et al. (1988)
- Croen et al. (2019) (PDF)
- Curran et al. (2015)
- D Onofrio et al. (2013)
- De Sutter et al. (2020)
- Dean et al. (2012)
- Delobel-Ayoub et al. (2020)
- DeWall et al. (2010)
- Dobra et al. (2025)
- Donohue (2006)
- Durso et al. (2015)
- Dutheil et al. (2009)